Clinical Reason Statement A Clinical Reason Statement is required when prescribing Semaglutide
The potential link between GLP-1 therapies and gout risk is gaining attention as clinicians look beyond glucose control to broader metabolic outcomes
The membrane was blocked for 2 h with 5% nonfat dry milk in TBS-Tween (TBS-T: 50 mM Tris-HCl, 150 mm NaCl, and 0.1% Tween 20 (pH 7.4)), and then incubated overnight at 4 C with 1.78 g/ml GLP1R-specific antibody (MAb 3F52) 24 in TBS-T
Saunte DML, Holgersen JB, Hdersdal M, et al
They are not independently verified, not controlled observations, and not representative of all users
All authors are joint guarantors of this work and, as such, had full access to all of the literature search results and references cited and take responsibility for the integrity of the data cited and the accuracy of the analyses provided